Compositions and applications for removing endotoxins from bovine serum

By treating bovine serum with a combination of Triton X-114 and 200-mesh activated carbon, combined with filter aids diatomaceous earth and perlite, the problem of endotoxin removal from bovine serum was solved, achieving efficient and low-cost endotoxin removal, which is suitable for vaccine production.

CN118045399BActive Publication Date: 2026-11-17JINYUBAOLING BIO PHARMA CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202211430127.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-11-15
Publication Date
2026-11-17
Estimated Expiration
2042-11-15

AI Technical Summary

Technical Problem

Existing technologies are insufficient to effectively remove endotoxins from bovine serum, and conventional methods can affect serum quality or are too costly, making large-scale production difficult.

Method used

Triton X-114 was used as the removal agent, combined with 200-mesh activated carbon as the adsorbent, and diatomaceous earth and perlite were used as filter aids. The process involved multiple steps, including adjusting the pH and temperature, to remove endotoxins from bovine serum.

Benefits of technology

It effectively reduces the endotoxin content in bovine serum by more than 96%, maintains the cell culture performance of serum, reduces hemoglobin and total protein content, is suitable for large-scale industrial production, and improves vaccine quality.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118045399B_ABST
    Figure CN118045399B_ABST
Patent Text Reader

Abstract

This invention provides a composition and its application for removing endotoxins from bovine serum, relating to the field of veterinary biological products technology. The composition for removing endotoxins from bovine serum includes a remover and an adsorbent; the remover includes Triton X-114; the adsorbent includes activated carbon. The remover effectively removes endotoxins from bovine serum, and the adsorbent effectively eliminates the adverse effects of the remover on the bovine serum. The composition for removing endotoxins from bovine serum provided by this invention can effectively reduce the endotoxin content in bovine serum without affecting the quality of the bovine serum product.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of veterinary biological products technology, and in particular to a composition for removing endotoxins from bovine serum and its application. Background Technology

[0002] Endotoxins are unique structures on the outer membrane of Gram-negative bacteria (GNB) cell walls. They are essentially lipopolysaccharides (LPS), chemically composed primarily of two parts: polysaccharide and lipid A. Lipid A is the active center of LPS, mainly composed of glucosamine and long fatty acids with 10-18 carbon atoms in phosphate. Under physiological conditions, it is hydrophobic and electronegative. When Gram-negative bacteria die, endotoxins are released into their environment. Humans (and animals) are extremely sensitive to endotoxins. When there are high levels of endotoxins in the blood of humans (or animals), or when large amounts of endotoxin-contaminated preparations are administered, it can lead to severe fever, endotoxemia, and even death. Therefore, minimizing the endotoxin content in preparations is crucial.

[0003] Bovine serum is a crucial raw material in vaccine production, and the endotoxins it contains are highly likely to end up in the final formulation. Both the Chinese Pharmacopoeia and the Chinese Veterinary Pharmacopoeia specify clear requirements for the endotoxin content in bovine serum. However, endotoxins are characterized by their small size, high thermal stability, and strong chemical stability. They generally exist in aggregate form, and their phosphate groups chelate with divalent metal ions (e.g., calcium ions), further stabilizing the aggregation between endotoxin molecules and promoting larger endotoxin complexes with molecular weights ranging from several thousand to tens of millions. For these reasons, removing endotoxins is extremely difficult.

[0004] Currently, both commercially available and literature sources describe methods for removing endotoxins. However, after verification and optimization of these methods, it has been found that most methods cause bovine serum to lose its cell culture performance (e.g., various chemical methods, including hydrogen peroxide treatment and potassium dichromate treatment; liquid phase separation, etc.); some methods have relatively small impacts on bovine serum quality, but are too costly and difficult to replicate or scale up (e.g., affinity chromatography); some methods result in significant losses and are not worthwhile (e.g., ultrafiltration, molecular sieves, etc.); and some have no significant effect or are unsuitable for bovine serum containing complex protein components (e.g., ion chromatography, hydrophobic chromatography, etc.). In summary, existing endotoxin removal methods, or methods with appropriate modifications based on described methods, are not suitable for removing endotoxins from substances containing complex protein components, such as bovine serum. Summary of the Invention

[0005] In view of the technical problems existing in the background art and the urgent needs in this field, the present invention provides a composition and its application for removing endotoxins from bovine serum. The technical solution provided by the present invention can effectively reduce the endotoxin content in bovine serum without affecting the quality of the bovine serum product. Specifically, it improves key indicators such as cell culture performance and other basic physicochemical indicators. The technical solution provided by the present invention has advantages such as good reproducibility, ease of scale-up, simple operation, and suitability for large-scale industrial production.

[0006] The present invention provides a composition for removing endotoxins from bovine serum, comprising a remover and an adsorbent, wherein the remover comprises Triton X-114 and the adsorbent comprises activated carbon.

[0007] Preferably, the removal agent includes Triton X-114, and also includes one or more of Triton X-110, Tween-20, Tween-40 and Tween-80; the Triton X-114 in the removal agent has a mass percentage content of ≥70%;

[0008] More preferably, the Triton X-110 in the removal agent has a mass percentage content of 0%-20%; the Tween-20 in the removal agent has a mass percentage content of 0%-10%; the Tween-40 in the removal agent has a mass percentage content of 0%-5%; the Tween-80 in the removal agent has a mass percentage content of 0%-10%; and the Triton X-114 in the removal agent has a mass percentage content of 70%-100%.

[0009] In a preferred embodiment, the removal agent comprises: Triton X-110 in the removal agent at a mass percentage of 0%-10%; Tween-20 in the removal agent at a mass percentage of 0%-5%; Tween-40 in the removal agent at a mass percentage of 0%-5%; Tween-80 in the removal agent at a mass percentage of 0%-5%; and Triton X-114 in the removal agent at a mass percentage of 80%-100%.

[0010] In a preferred embodiment, the removal agent comprises: Triton X-110 in the removal agent at a mass percentage of 0%-10%; Tween-20 in the removal agent at a mass percentage of 0%-10%; Tween-40 in the removal agent at a mass percentage of 0%-5%; Tween-80 in the removal agent at a mass percentage of 0%-10%; and Triton X-114 in the removal agent at a mass percentage of 75%-100%.

[0011] Preferably, the adsorbent comprises 200-mesh activated carbon, and further comprises one or more of macroporous resin, dextran, 60-mesh activated carbon, and 100-mesh activated carbon; the 200-mesh activated carbon comprises ≥50% by mass in the adsorbent.

[0012] The activated carbon standard described in this invention is determined in conjunction with commonly used standards in the field, specifically as follows:

[0013] The required proportion of ≥200 mesh activated carbon is 99% or higher.

[0014] 60-mesh activated carbon requires that 30-60 mesh activated carbon account for more than 95% of the total.

[0015] 100-mesh activated carbon requires that 90-110 mesh activated carbon account for more than 95% of the total.

[0016] More preferably, the macroporous resin in the adsorbent comprises 0%-20% by mass; the dextran in the adsorbent comprises 0%-20% by mass; the 60-mesh activated carbon in the adsorbent comprises 0%-20% by mass; the 100-mesh activated carbon in the adsorbent comprises 0%-30% by mass; and the 200-mesh activated carbon in the adsorbent comprises 50%-100% by mass.

[0017] In a preferred embodiment, the adsorbent comprises: the macroporous resin in the adsorbent having a mass percentage content of 0%-10%; the dextran in the adsorbent having a mass percentage content of 0%-2%; the 60-mesh activated carbon in the adsorbent having a mass percentage content of 0%-5%; the 100-mesh activated carbon in the adsorbent having a mass percentage content of 0%-10%; and the 200-mesh activated carbon in the adsorbent having a mass percentage content of 70%-100%.

[0018] In a preferred embodiment, the adsorbent comprises: the macroporous resin comprising 0%-5% by mass; the dextran comprising 0%-5% by mass; the 60-mesh activated carbon comprising 0%-10% by mass; the 100-mesh activated carbon comprising 0%-5% by mass; and the 200-mesh activated carbon comprising 75%-100% by mass.

[0019] Preferably, the composition for removing endotoxins from bovine serum includes a remover and an adsorbent, and further includes a filter aid; the filter aid includes diatomaceous earth and / or perlite;

[0020] More preferably, the filter aid comprises diatomaceous earth and perlite; the mass ratio of the diatomaceous earth to perlite is (2-4):(0.5-1.5).

[0021] The present invention provides the application of the composition for removing endotoxins from bovine serum in the removal of endotoxins from bovine serum.

[0022] This invention provides a method for removing bovine serum endotoxins, comprising the following steps:

[0023] S1. Add the removal agent from the composition for removing endotoxins from bovine serum to bovine serum. After the removal agent has completed its action, the initial serum is obtained.

[0024] S2. Add the adsorbent from the composition for removing endotoxins from bovine serum to the initial serum. After the adsorbent has completed its action, a deeply adsorbed serum is obtained.

[0025] Preferably, the amount of the removal agent added in step S1 is 0.1%-2% by mass-volume ratio;

[0026] Preferably, the amount of adsorbent added in step S2 is 2%-15% by mass-volume ratio.

[0027] Preferably, the removal agent in step S1 acts for 1-3 hours; the adsorbent in step S2 acts for 2-6 hours.

[0028] Preferably, before adding the removal agent in step S1, HCl solution is added to the bovine serum to adjust the pH value to 4.0-6.5;

[0029] Preferably, the concentration of the HCl solution is 0.1-2M.

[0030] Preferably, after step S2, the following steps are also included:

[0031] S3. Add the filter aid to the deeply adsorbed serum, and obtain clear serum after filtration;

[0032] Preferably, the amount of filter aid added in step S3 is 1%-5% by mass-volume ratio.

[0033] Preferably, after step S3, the following steps are also included:

[0034] S4. Add NaOH solution to the clarified serum, adjust the pH to 7.0-8.5, and filter to remove bacteria;

[0035] Preferably, the concentration of the NaOH solution is 0.1-2M.

[0036] The present invention also provides the composition for removing endotoxins from bovine serum, or the application of the bovine serum endotoxin removal method in vaccine production.

[0037] Beneficial effects:

[0038] This invention provides a composition for removing endotoxins from bovine serum, comprising a remover and an adsorbent, wherein the remover includes Triton X-114; and the adsorbent includes activated carbon. The remover effectively removes endotoxins from bovine serum, and the adsorbent effectively mitigates the adverse effects of the remover on the bovine serum. The composition for removing endotoxins from bovine serum provided by this invention effectively reduces the endotoxin content in bovine serum without affecting the quality of the bovine serum product.

[0039] This invention provides the application of the composition for removing endotoxins from bovine serum in the removal of bovine serum endotoxins, and further provides a specific method for removing bovine serum endotoxins. The bovine serum endotoxin removal method of this invention can effectively reduce the endotoxin content in bovine serum, with a removal efficiency of over 96%; while reducing bovine serum endotoxins, it can still maintain, and even improve, the cell culture performance of bovine serum; and while reducing endotoxins, it also reduces the total protein content and hemoglobin content of the serum, which is beneficial for the purification process in the later stages of vaccine development.

[0040] The bovine serum endotoxin removal method provided by this invention fills the gap in large-scale production of low-endotoxin bovine serum. It has the advantages of good reproducibility, stable process, simple operation, and easy scale-up. It can appropriately improve serum quality, which is beneficial to the improvement of vaccine quality. It can also reduce the pressure on downstream processes during vaccine development and reduce the total protein content of the vaccine. Attached Figure Description

[0041] To more clearly illustrate the technical solutions in this invention or the prior art, the accompanying drawings used in the description of the embodiments or the prior art will be described below.

[0042] Figure 1 This describes the effect of the removal agent's operating temperature on endotoxin content in Example 1 of the present invention.

[0043] Figure 2 This describes the effect of the removal agent's action time on endotoxin content in Example 1 of the present invention;

[0044] Figure 3 This refers to the results of the BHK21 cell growth experiment in Example 7 of this invention;

[0045] Figure 4 This refers to the PK15 cell growth experiment results in Example 7 of this invention;

[0046] Figure 5 This refers to the results of the Vero cell growth experiment in Example 7 of this invention;

[0047] Figure 6 This is the result of the ST cell growth experiment in Example 7 of the present invention. Detailed Implementation

[0048] This invention provides a composition for removing endotoxins from bovine serum, comprising a remover and an adsorbent, wherein the remover includes Triton X-114 and the adsorbent includes activated carbon. In this invention, the remover effectively removes endotoxins from bovine serum, and the adsorbent effectively eliminates the adverse effects of the remover on the bovine serum. The composition for removing endotoxins from bovine serum provided by this invention can effectively reduce the endotoxin content in bovine serum without affecting the quality of the bovine serum product.

[0049] In a preferred embodiment of the present invention, the removal agent includes Triton X-114, and further includes one or more of Triton X-110, Tween-20, Tween-40, and Tween-80. The Triton X-114 in the removal agent comprises 70%-100% by mass, preferably 80%-90%, more preferably 85%; the Triton X-110 in the removal agent comprises 0%-20% by mass, preferably 0%-10%, more preferably 4%-6%, and most preferably 5%; the Tween-20 in the removal agent comprises 0%-10% by mass, preferably 0%-5%, more preferably 5%; the Tween-40 in the removal agent comprises 0%-5% by mass; and the Tween-80 in the removal agent comprises 0%-10% by mass, preferably 0%-5%, more preferably 5%. The present invention does not impose any particular limitation on the source of the TritonX-110, TritonX-114, Tween-20, Tween-40 and Tween-80, and all of them can be from commercially available sources in the art.

[0050] In a preferred embodiment of the present invention, the adsorbent comprises 200-mesh activated carbon, and further comprises one or more of macroporous resin, dextran, 60-mesh activated carbon, and 100-mesh activated carbon. The 200-mesh activated carbon comprises 50%-100% by mass, preferably 70%-80%, more preferably 75%; the macroporous resin comprises 0%-20% by mass, preferably 4%-6%, more preferably 5%; the dextran comprises 0%-20% by mass, preferably 0%-10%, more preferably 5%; the 60-mesh activated carbon comprises 0%-20% by mass, preferably 0%-10%, more preferably 5%; and the 100-mesh activated carbon comprises 0%-30% by mass, preferably 0%-10%, more preferably 10%. In the present invention, the macroporous resin is preferably 20-60 mesh, and the dextran is preferably 10000-25000 Mw. The present invention does not impose any particular limitation on the source of the macroporous resin, the dextran, the 60-mesh activated carbon, the 100-mesh activated carbon, and the 200-mesh activated carbon; all commercially available sources in the art are acceptable.

[0051] In a preferred embodiment of the present invention, the composition for removing endotoxins from bovine serum includes a remover and an adsorbent, and further includes a filter aid; the filter aid includes diatomaceous earth and / or perlite. The filter aid preferably includes diatomaceous earth and perlite; the mass ratio of diatomaceous earth to perlite is preferably (2-4):(0.5-1.5), more preferably 3:1. In the present invention, the diatomaceous earth is preferably 20-40 μm (neutral particle size), and the perlite is preferably 30-60 relative flow rate (s / 100ml). The present invention does not particularly limit the source of the diatomaceous earth and the perlite; conventional commercial sources in the art are acceptable.

[0052] The present invention provides the application of the composition for removing endotoxins from bovine serum in the removal of endotoxins from bovine serum.

[0053] Furthermore, the present invention provides a method for clearing bovine serum endotoxin, comprising the following steps:

[0054] S1. Add the removal agent from the composition for removing endotoxins from bovine serum to bovine serum. After the removal agent has completed its action, the initial serum is obtained.

[0055] S2. Add the adsorbent from the composition for removing endotoxins from bovine serum to the initial serum. After the adsorbent has completed its action, a deeply adsorbed serum is obtained.

[0056] Step S1 of the present invention preferably includes: adding a removal agent to bovine serum, and after the action is completed, collecting the serum to obtain the initial serum extract.

[0057] In some preferred embodiments, after the bovine serum is thawed in step S1, HCl solution is added while stirring to adjust the pH, and then a removal agent is added. After stirring and mixing, the mixture is stirred for 1-3 hours to obtain the initial serum extract.

[0058] In some preferred embodiments, step S1 adjusts the pH to 4.0-6.5, preferably 5.0-6.5. A pH range of 5.0-6.5 is more conducive to ensuring the bioactivity of complex protein components in bovine serum.

[0059] In some preferred embodiments, the concentration of the HCl solution used to adjust the pH in step S1 is 0.1M-2M, preferably 0.5M-2M.

[0060] In some preferred embodiments, the amount of the remover added in step S1 is 0.1%-2%, preferably 0.5%-1.5%, based on a mass-volume ratio (w / v, in g / 100ml; for example, a mass-volume ratio of 2% means 2g / 100ml).

[0061] In some preferred embodiments, the stirring temperature in step S1 is 0°C-20°C.

[0062] In some preferred embodiments, the operating temperature in step S1 varies with the operating time, and its temperature range is 0℃-25℃, preferably 2℃-20℃ (see...). Figure 1 ).

[0063] Step S2 of the present invention preferably includes: adding an adsorbent to the obtained initial serum, using the adsorbent that has been depyrogenated to continuously act on the initial serum obtained in step S1, and after deep adsorption is completed, centrifuging to collect the supernatant to obtain serum after deep adsorption.

[0064] In some preferred embodiments, the amount of adsorbent added in step S2 is 2%-15%, preferably 5%-10%, based on a mass-volume ratio (w / v, in g / 100ml; for example, a mass-volume ratio of 2% means 2g / 100ml).

[0065] In some preferred embodiments, after adding the adsorbent in step S2, the mixture is stirred and mixed every 10 minutes; the reaction time is 2-6 hours, preferably 2.5-5 hours.

[0066] In some preferred embodiments, the operating temperature in step S2 is 0℃-25℃, preferably 4℃-20℃.

[0067] In some preferred embodiments, the centrifugation speed in step S2 is 6000-10000 rpm and the centrifugation time is 10-20 min.

[0068] The bovine serum endotoxin removal method provided by this invention can be repeated in actual production processes according to actual needs, with steps S1 and S2 being repeated as needed.

[0069] The bovine serum endotoxin removal method provided by the present invention preferably includes step S3 after step S2: adding the filter aid to the deeply adsorbed serum, and obtaining clear serum after filtration.

[0070] Step S3 of the present invention preferably includes: adding a filter aid to the deeply adsorbed serum obtained in S2, and circulating and filtering until clear to obtain clear serum.

[0071] In some preferred embodiments, the amount of filter aid added in step S3 is 1%-5% by mass-volume ratio (g / ml).

[0072] In some preferred embodiments, the filter pore size involved in the circulating filtration in step S3 is 0.8-1 μm.

[0073] In some preferred embodiments, the filter mentioned in step S3 is one or two of titanium rod filters and depth filters connected in series.

[0074] In some preferred embodiments, the circulating filtration time in step S3 is not less than 15 minutes, and more preferably 20-40 minutes.

[0075] In some preferred embodiments, during the circulating filtration process in step S3, the temperature is controlled at 0℃-20℃, preferably 10℃-20℃.

[0076] The bovine serum endotoxin removal method provided by the present invention preferably further includes step S4 after step S3: adding NaOH solution to the clarified serum, adjusting the pH value to 7.0-8.5, and filtering for sterilization;

[0077] Step S4 of the present invention preferably includes: adding NaOH solution to the clarified serum obtained in S3, adjusting the pH to 7.0-8.5, and then filtering and sterilizing step by step with a filter element with a pore size of 0.45μm-0.22μm-0.1μm to obtain bovine serum with low endotoxin content.

[0078] In some preferred embodiments, in step S4, NaOH solution is first added to the clear serum obtained in S3 to adjust the pH to 7.0-8.5. Then, the serum is filtered step by step with a filter element with a pore size of 0.45μm-0.22μm-0.1μm to remove bacteria, and then frozen at -15°C for later use to obtain the final low endotoxin bovine serum.

[0079] In some preferred embodiments, the concentration of the NaOH solution in step S4 is 0.1M-2M, preferably 0.5M-2M.

[0080] The present invention preferably tests the bovine serum with low endotoxin content obtained in step S4. The tests preferably include: bacterial endotoxin content detection, total protein content detection, hemoglobin detection, SP2 / 0 cell proliferation test, and cell (BHK21, Vero, ST, PK15, Marc145, hybridoma cells, etc.) growth test (not less than 6 generations).

[0081] The bovine serum endotoxin removal method provided by this invention can effectively reduce the endotoxin content in bovine serum without affecting the product quality, thus solving existing technical problems. This method has good repeatability, is easy to scale up, and is simple to operate, making it suitable for large-scale industrial production.

[0082] The present invention also provides the composition for removing endotoxins from bovine serum, or the application of the bovine serum endotoxin removal method in vaccine production.

[0083] The bovine serum produced using the technical solution provided by this invention has low endotoxin content, low hemoglobin content, and qualified and low total protein content, which can maintain and improve the cell culture performance of bovine serum; it is more conducive to improving the quality of vaccine products, reducing the pressure on downstream processes during production, and reducing the total protein content of vaccines.

[0084] To make the objectives, technical solutions, and advantages of this invention clearer, the technical solutions of this invention will be clearly and completely described below in conjunction with embodiments. Obviously, the described embodiments are only some embodiments of this invention, not all embodiments. Based on the embodiments of this invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of this invention.

[0085] The methods for obtaining various biological materials described in the embodiments are merely to provide experimental methods for specific disclosure purposes and should not be construed as limiting the sources of biological materials used in this invention. In fact, the sources of biological materials used are wide-ranging, and any biological material that can be obtained without violating laws and ethical standards can be substituted and used according to the suggestions in the embodiments.

[0086] Where specific techniques or conditions are not specified in the embodiments, they shall be performed in accordance with the techniques or conditions described in the literature in this field, or in accordance with the product manual. Instruments and other equipment whose manufacturers are not specified are all conventional products that can be purchased through legitimate channels. Unless otherwise specified, the methods described are conventional methods, and the raw materials described are all obtainable from publicly available commercial sources. Where specific techniques or conditions are not specified in the embodiments, they shall be performed in accordance with the techniques or conditions described in the literature in this field, or in accordance with the product manual.

[0087] The reagents used in the embodiments of this invention include: Triton X-110 (purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., item number: T109027); Triton X-114 (purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., item number: T101474); Tween-20 (purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., item number: T104863); Tween-40 (purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., item number: T112748); Tween-80 (purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., item number: T118633); macroporous resin (purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., item number: A109917); and dextran. (Purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., item number: D140039); Powdered activated carbon (purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., item numbers: C299186, C299105, C112241); Diatomaceous earth (purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., item number: K131664); Perlite (purchased from Shanghai Myriel Biochemical Technology Co., Ltd., item number: GEL-SIP6720.73); Adult bovine serum (purchased from Thermo Fisher Scientific, item number: 26170043), Fetal bovine serum (purchased from Inner Mongolia Jinyuankang Bioengineering Co., Ltd., item number: BS1103), Newborn bovine serum (purchased from Inner Mongolia Jinyuankang Bioengineering Co., Ltd., item number: BS1305)

[0088] Example 1

[0089] (1) Initial extraction of endotoxin: Take an appropriate amount of fetal bovine serum, and after it is slowly thawed, add HCl solution while stirring to adjust the pH to 5.5. Add a removal agent, and after stirring until well mixed, continue stirring. Take samples at regular intervals to detect the endotoxin content. After the endotoxin level is significantly reduced, collect the serum for later use.

[0090] The concentration of the HCl solution is 1M. Removal agent-1 is selected, and the proportions of each component are shown in Table 1.

[0091] Table 1. Proportion of each component in remover-1

[0092] name Triton X-110 TritonX-114 Tween-20 Tween-80 Remover-1 5% 85% 5% 5%

[0093] The removal agent was added at a rate of 1% (w / v). The stirring temperature was 4°C. The action temperature of the removal agent varied with the action time; that is, it was acted at 4°C for the first 30 minutes, and then the temperature was gradually increased at 10-minute intervals, with an increase of 5°C-6°C, until it reached 20°C. The action time was 2 hours.

[0094] The inventors conducted a more detailed study on the operating temperature, and the results showed that the suitable operating temperature range is 0℃-25℃, with an even better range of 2℃-20℃ (see results). Figure 1 Furthermore, the inventors improved the process by gradually increasing the temperature over time. On the other hand, they also experimented with the optimal contact time, finding that 1-3 hours was the best time; after 4 hours, the endotoxin level gradually increased with prolonged contact time (see results). Figure 2 Therefore, it is recommended that the treatment time be controlled within 1-3 hours.

[0095] (2) Deep adsorption: Add adsorbent to the serum treated in step (1), stir continuously until all adsorbent is fully combined with the serum, and then continue to act. Stir evenly every 10 minutes, and take samples at regular intervals to detect the endotoxin content. After deep adsorption is completed, centrifuge and collect the supernatant for later use.

[0096] Among them, the adsorbent selected is Adsorbent-1, and the proportion of each component is shown in Table 2.

[0097] Table 2. Proportion of each component in the adsorbent

[0098]

[0099] The adsorbent needs to be depyrogened before use to prevent an increase in serum endotoxin levels due to pyrogens introduced by the reagent. The depyrogenosis method should be selected based on the characteristics of each reagent, and should conform to the methods specified in the Chinese Pharmacopoeia or the Chinese Veterinary Pharmacopoeia. The adsorbent addition amount is 8%. The stirring time is 3 hours. The operating temperature is 18℃. The centrifugation speed is 10000 rpm, and the centrifugation time is 15 minutes.

[0100] (3) Clarification: Add a filter aid to the serum processed in step (2) and circulate the filter until it is clear, that is, there is no color difference between the inlet and outlet and the liquid is clear. Collect the clarified serum for later use.

[0101] The filter aid is a mixture of diatomaceous earth and perlite at a mass ratio of 3:1. The amount of filter aid added is 2%.

[0102] Before use, the filter aid must be depyrogenated to prevent an increase in serum endotoxin levels due to pyrogens introduced by the reagent. The depyrogenation method should be selected appropriately based on the characteristics of each reagent, and should conform to the methods specified in the Chinese Pharmacopoeia or the Chinese Veterinary Pharmacopoeia. The filter pore size for the circulating filtration is 0.8-1µm. The filter consists of two types connected in series: a titanium rod filter and a depth filter. The circulating filtration time is 25 minutes. During the circulating filtration process, the temperature should be controlled between 10℃ and 20℃.

[0103] (4) Sterilization: Add NaOH solution to the serum processed in step (3) and adjust the pH to 7.0-8.5. Then, filter the serum step by step with a filter element with a pore size of 0.45μm-0.22μm-0.1μm to sterilize it. Perform cell growth test and endotoxin test on the sterilized serum and freeze it below -15℃ for later use.

[0104] The concentration of the NaOH solution is 1M.

[0105] Using the method described in this embodiment, the removal rate of endotoxins in fetal bovine serum can reach over 98%, the hemoglobin content is significantly reduced, and cell culture performance is not adversely affected, and occasionally even improved. The serum treated by the method described in this embodiment (treated - H) showed consistent cell morphology in cell growth assays compared to the serum before treatment (untreated - W).

[0106] Example 2

[0107] This embodiment removes endotoxins according to the method described in Embodiment 1. The method and process used are the same as in Embodiment 1, except that the sample being treated is changed from fetal bovine serum to newborn bovine serum.

[0108] Using the method described in this embodiment, the removal rate of endotoxin in newborn calf serum can reach over 98%, the hemoglobin content is significantly reduced, and cell culture performance is not adversely affected, and occasionally even improved. The serum treated by the method described in this embodiment (treated - H) showed consistent cell morphology in cell growth assays compared to the serum before treatment (untreated - W).

[0109] Example 3

[0110] This embodiment removes endotoxins according to the method described in Embodiment 1. The method and process used are the same as in Embodiment 1, except that the sample being treated is changed from fetal bovine serum to adult bovine serum.

[0111] Using the method described in this embodiment, the removal rate of endotoxins in adult bovine serum can reach over 98%, the hemoglobin content is significantly reduced, and cell culture performance is not adversely affected, and occasionally even improved. Serum treated by the method described in this embodiment (treated - H) showed, in cell growth assays, that the cell morphology was superior to or consistent with that of untreated serum (untreated - W).

[0112] Example 4

[0113] This embodiment removes endotoxins according to the method described in Example 1. The procedure is the same as in Example 1, except that the formulation of the removal agent is changed. Removal agent-2 and removal agent-3 are used, and the specific formulation composition is shown in Table 3. The sample being treated is changed from fetal bovine serum to adult bovine serum.

[0114] Table 3. Proportion of each component in the removal agent

[0115] name Triton X-110 TritonX-114 Tween-20 Tween-40 Tween-80 Remover-2 10% 80% 3% 2% 5% Remover-3 10% 75% 5% 5% 10%

[0116] Using the method described in this embodiment, the removal rate of endotoxins in adult bovine serum can reach over 96%, the hemoglobin content is significantly reduced, and cell culture performance is not adversely affected, with occasional improvement. The serum treated by the method described in this embodiment (treated - H) showed that the cell morphology remained consistent with that of the untreated serum (untreated - W) in cell growth assays.

[0117] Example 5

[0118] This embodiment removes endotoxins according to the method described in Example 1. The procedure is the same as in Example 1, except that the adsorbent formulation is changed. Adsorbent-2 and Adsorbent-3 are used, and the specific formulation is shown in Table 4. The sample being treated is changed from fetal bovine serum to adult bovine serum.

[0119] Table 4. Proportion of each component in the adsorbent

[0120]

[0121] Using the method described in this embodiment, the removal rate of endotoxins in adult bovine serum can reach over 96%, the hemoglobin content is significantly reduced, and cell culture performance is not adversely affected, with occasional improvement. The serum treated by the method described in this embodiment (treated - H) showed that the cell morphology remained consistent with that of the untreated serum (untreated - W) in cell growth assays.

[0122] Example 6

[0123] Comparison of endotoxin removal effects: The embodiments (Examples 1-5) involved in this invention all require the removal of endotoxins under acidic conditions first, followed by the adsorption of the removal agent by an adsorbent, then the removal of the adsorbent by a clarification step, and finally filtration and sterilization to obtain the final serum.

[0124] (1) This study compared the removal effects under different pH conditions. The results showed that the suitable pH range was 4.0-6.5, preferably 5.0-6.5. This is because serum proteins are complex, and prolonged exposure to excessively low pH conditions is not conducive to maintaining the activity of certain proteins, while the removal effect of endotoxins is poor at pH values ​​above 6.5. See Table 5 for detailed data.

[0125] Table 5 Comparison of the effects of pH on removal efficiency

[0126]

[0127]

[0128] (2) In this embodiment, the serum treated by the methods described in Examples 1-5 and the untreated serum were tested and compared. The results showed that all embodiments of the present invention can effectively remove endotoxins from bovine serum (including fetal bovine serum, newborn bovine serum, and adult bovine serum), with a removal efficiency of not less than 96%. In particular, the removal efficiency of Examples 1-3 is not less than 98%. At the same time, the methods described in the embodiments of the present invention can also reduce the hemoglobin content in bovine serum. The detection items described in this embodiment are: bacterial endotoxin content detection, total protein content detection, osmotic pressure, and hemoglobin detection. Among them, the bacterial endotoxin content detection, total protein content detection, and osmotic pressure test items were all tested according to the methods specified in the Chinese Veterinary Pharmacopoeia, and the hemoglobin detection test items were all tested according to the methods specified in the Chinese Pharmacopoeia. See Table 6 for detailed data.

[0129] Table 6 Comparison of detection parameters before and after serum treatment

[0130]

[0131]

[0132] Example 7

[0133] Cell Culture Performance Comparison: This embodiment compares and performs cell culture-related tests on the serum from Examples 1-5. The results show that the bovine serum (including fetal bovine serum, newborn calf serum, and adult bovine serum) treated in each embodiment of this invention (post-treatment - H) can maintain or slightly improve upon the levels before treatment (untreated W). Furthermore, the methods described in each embodiment of this invention do not show significant differences in cell culture performance. The cell culture-related tests include: SP2 / 0 cell proliferation assay and cell (BHK21, Vero, ST, PK15, Marc145, hybridoma cells, etc.) growth assay (at least 6 passages).

[0134] (1) The SP2 / 0 cell proliferation assay was performed according to the method specified in the Chinese Veterinary Pharmacopoeia. The SP2 / 0 cell proliferation assay results showed that the serum treated with the method described in this invention was superior to the untreated serum. Overall, the increase in adult bovine serum was the greatest, while the increases in newborn calf serum and fetal bovine serum were relatively smaller. This may be related to the better culture performance of fetal bovine serum and newborn calf serum. See Table 7 for detailed data.

[0135] Table 7 Comparison of SP2 / 0 cell proliferation test results before and after serum treatment.

[0136]

[0137]

[0138] (2) In this embodiment, the cell growth experiment was performed as follows: The serum to be tested was taken and added to DMEM solution at a concentration of 7% (v / v) to prepare cell culture medium for later use. Then, cells that had grown to a good monolayer (BHK21, Vero, ST, PK15, Marc145, hybridoma cells, etc.) were taken, digested with trypsin, and counted. Based on the counting results, the cells were diluted with cell culture medium to 70,000-90,000 cells / ml. The diluted cell solution was then transferred to a cell culture flask (3L roller flask) and cultured at 37°C, 5% CO2, and 10r / h. After the cells grew to a good monolayer, they were passaged and seeded according to this method, and passaged for 6 or more generations. The cell proliferation rate was calculated, the growth cycle was recorded, and the cell morphology was observed daily.

[0139] BHK21 cell growth assays showed that in all examples, the treated and untreated serum levels were the same, and the cells exhibited good morphology and no abnormalities (see [link to BHK21 cell growth assay]). Figure 3 The growth patterns were consistent across all samples. Particularly in Example 1, the cell culture performance was improved after treatment compared to untreated serum. See Table 8 for detailed data.

[0140] Table 8 BHK before and after serum treatment 21 Summary of cell growth assay results

[0141]

[0142]

[0143] Note: Growth characteristics refer to the time required from the date of cell passage to the formation of a good monolayer. If there are abnormalities in cell morphology, the text will be in bold. No abnormalities in cell morphology were observed in this experiment.

[0144] Vero cell growth assays showed that in all examples, the treated and untreated serum were at the same level, and the cells were morphologically sound and showed no abnormalities (see...). Figure 5 The growth patterns are consistent across all species. See Table 9 for detailed data.

[0145] Table 9 Summary of Vero cell growth assay results before and after serum treatment

[0146]

[0147]

[0148] Note: Growth characteristics refer to the time required from the date of cell passage to the formation of a good monolayer. If there are abnormalities in cell morphology, the text will be in bold. No abnormalities in cell morphology were observed in this experiment.

[0149] ST cell growth assays showed that in all examples, the treated and untreated serums were at the same level, with normal cell morphology and consistent growth patterns. Detailed data are shown in Table 10. Particularly in Example 3, the cell morphology of the treated serum was significantly improved compared to the untreated serum: ST cells cultured with untreated serum had clearly defined intercellular spaces and visible cytoplasmic outlines; while ST cells cultured with treated serum had indistinct intercellular spaces and indistinct cytoplasmic outlines. Clearly, the ST cells cultured with treated serum better conformed to the morphological characteristics of this cell type (see Table 10). Figure 6 ).

[0150] Table 10 Summary of ST cell growth assay results before and after serum treatment

[0151]

[0152]

[0153] Note: Growth characteristics refer to the time required from the date of cell passage to the formation of a good monolayer. If there are abnormalities in cell morphology, the text will be in bold. No abnormalities in cell morphology were observed in this experiment.

[0154] PK15 cell growth assays showed that in all examples, the treated and untreated serum levels were the same, and the cells exhibited good morphology and no abnormalities (see [link to assay]). Figure 4 The growth patterns are consistent across all species. See Table 11 for detailed data.

[0155] Table 11 Summary of PK15 cell growth assay results before and after serum treatment

[0156]

[0157]

[0158] The composition and method for removing endotoxins from bovine serum provided by this invention can effectively reduce the endotoxin content in bovine serum, achieving a removal efficiency of over 96%, especially in Example 1 where the removal efficiency reaches over 98%. Using the method described in this invention, bovine serum with an initial endotoxin level of approximately 200 Eu / ml can be reduced to <0.03 Eu / ml; bovine serum with an initial endotoxin level of approximately 700 Eu / ml can be reduced to 3 Eu / ml-7 Eu / ml; and bovine serum with an initial endotoxin level of approximately 1400 Eu / ml can be reduced to 7 Eu / ml-20 Eu / ml. Furthermore, it should be noted that this invention allows for the repetition of individual steps depending on the initial endotoxin level, further reducing the endotoxin content to even lower levels.

[0159] The composition and method for removing endotoxins from bovine serum provided by this invention can maintain or even improve the original cell culture performance of bovine serum while reducing endotoxin levels. Results from the examples show that in SP2 / 0 cell proliferation assays, bovine serum treated with the method described in this invention is more conducive to cell proliferation; in BHK21 (and ST, Vero, PK15, Marc145, etc.) cell growth assays, serum treated with the method described in this invention is more conducive to cell growth and proliferation, and cell morphology can be maintained at the original level. In particular, in ST cell growth assays, serum treated with the method described in Example 3 showed that the ST cells cultured from the treated bovine serum had significantly better morphology than those cultured from untreated serum.

[0160] The composition and method for removing endotoxins from bovine serum provided by this invention can effectively remove endotoxins and hemoglobin while effectively maintaining the original characteristics and quality of the serum, with improvements in most features. Furthermore, the composition and method for removing endotoxins from bovine serum provided by this invention are applicable to fetal bovine serum, newborn bovine serum, and adult bovine serum.

[0161] Based on the similarity of various serum components, the composition and method for removing endotoxins from bovine serum provided by this invention also have the potential to be applied to other animal serums such as horse serum and pig serum.

[0162] The above embodiments are only used to illustrate the technical solutions of the present invention, and are not intended to limit it. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some of the technical features. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A method for clearing bovine serum endotoxins, characterized in that, Includes the following steps: S1. Add the removal agent from the composition used to remove endotoxins from bovine serum to the bovine serum. After the removal agent has completed its action, the initial serum is obtained. S2. Add the adsorbent from the composition for removing endotoxins from bovine serum to the initial serum. After the adsorbent has completed its action, a deeply adsorbed serum is obtained. S3. Add a filter aid to the deeply adsorbed serum, and filter to obtain clear serum; S4. Add NaOH solution to the clarified serum, adjust the pH to 7.0-8.5, and filter to remove bacteria; The composition for removing endotoxins from bovine serum comprises a remover and an adsorbent, wherein the remover comprises Triton X-114, Triton X-110, Tween-20, and Tween-80; the Triton X-114 comprises 80%-90% by mass in the remover; the Triton X-110 comprises 4%-6% by mass in the remover; the Tween-20 comprises 5% by mass in the remover; and the Tween-80 comprises 5% by mass in the remover. The adsorbent comprises macroporous resin, dextran, 60-mesh activated carbon, and 200-mesh activated carbon; the macroporous resin comprises 4%-6% by mass in the adsorbent; the dextran comprises 5% by mass in the adsorbent; the 60-mesh activated carbon comprises 5% by mass in the adsorbent; and the 200-mesh activated carbon comprises 75%-80% by mass in the adsorbent. The filter aid comprises diatomaceous earth and perlite; the mass ratio of diatomaceous earth to perlite is (2-4):(0.5-1.5). Before adding the removal agent in step S1, add HCl solution to the bovine serum to adjust the pH to 4.0-6.5; the action temperature of the removal agent varies with the action time, that is, it is acted at 4°C for the first 30 minutes, and then the temperature is gradually increased at 10-minute intervals, with an increase of 5°C-6°C, until it reaches 20°C; the action time of the removal agent in step S1 is 1-3 hours; the action time of the adsorbent in step S2 is 2-6 hours. The amount of the remover added in step S1 is 0.1%-2% by mass-volume ratio; the amount of the adsorbent added in step S2 is 2%-15% by mass-volume ratio; and the amount of the filter aid added in step S3 is 1%-5% by mass-volume ratio.

2. The bovine serum endotoxin removal method according to claim 1, characterized in that, The concentration of the HCl solution is 0.1-2M.

3. The bovine serum endotoxin removal method according to claim 1, characterized in that, The concentration of the NaOH solution is 0.1-2M.

4. The application of the bovine serum endotoxin removal method according to any one of claims 1 to 3 in vaccine production.

Citation Information

Patent Citations

  • Gelatin purification

    CN107580608A

  • Method for efficiently and conveniently removing endotoxin of albumin solution

    CN108084258A

  • Application of chitosan or derivative thereof in removal of endotoxin in gelatin

    CN115739031A